Connect with us
European Gaming Congress 2024

Artificial Intelligence

Harnessing Generative AI in Healthcare and Improving Cardiometabolic Health with Precision Medicine: Key Opportunities and Insights

Published

on

harnessing-generative-ai-in-healthcare-and-improving-cardiometabolic-health-with-precision-medicine:-key-opportunities-and-insights

HOUSTON, Oct. 22, 2024 /PRNewswire/ — In today’s rapidly evolving healthcare landscape, two powerful forces are reshaping how we diagnose, treat, and manage health conditions: Generative artificial intelligence (GenAI) and precision medicine for cardiometabolic health. GenAI promises to revolutionize operational efficiency, financial workflows, and clinical outcomes, while advancements in cardiometabolic treatments pave the way for personalized, patient-centered care. However, these innovations come with challenges, including data privacy concerns and the need for tailored therapeutic options.

Generative AI: Revolutionizing Healthcare Operations
GenAI, powered by advancements like ChatGPT-4, is reshaping healthcare by optimizing workflows, reducing costs, and improving patient care. However, to fully harness its capabilities, healthcare organizations must begin implementing GenAI in foundational areas such as documentation and knowledge management, before scaling across the healthcare value chain. Additionally, organizations need to address cybersecurity concerns, as healthcare faces a growing threat of cyberattacks, with projected costs reaching $90 trillion by 2030.
“Generative AI is transforming healthcare by streamlining/creating workflows, cutting costs, and enhancing patient care. It’s capacity for automation and enhanced decision-making support is critical for healthcare organizations focused on elevating patient outcomes and population health. However, to maximize its benefits, organizations should start with manageable use cases like documentation and knowledge management while also tackling adoption, integration, and cybersecurity challenges. Looking ahead, there are numerous opportunities—from next-generation digital front doors to automated prior authorization processes, and personalized communication, all designed to enhance provider, payer and patient experiences for better health outcomes.”
Nitin Manocha
Growth Expert & Senior Industry Analyst, Frost & Sullivan
Precision Medicine in Cardiometabolic Health
Cardiometabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease, are on the rise globally. Traditional treatment models often lack personalization and fail to address the unique needs of individual patients. Precision health aims to change this by integrating genomics, pharmacogenomics, and omics-based research to develop tailored therapies.
Key Opportunities for Stakeholders in Cardiometabolic Health
Glucagon-Like Peptide-1 (GLP-1)-Based Multi-Agonists: Focus on developing advanced therapies that offer effective weight loss with improved tolerability.Bioinformatics for Data-Driven Research: Harness data analytics to identify novel drug targets.Precision Health Partnerships: Collaborate in high-prevalence regions to enhance diabetes management through tailored interventions.Embrace the Future of Healthcare Innovation
For a deeper dive into these transformative trends, download our full analysis and join our upcoming webinars, where leading industry experts will discuss the role of GenAI and precision medicine in driving healthcare innovation.
Webinars:
Large Language Models and Generative AI in Healthcare: Exploring Best Practices & Competitive Positioning 
Next-Generation Cardiometabolic Health: Strategic Partnerships for Precision-Driven Innovation 
Stay ahead in the evolving healthcare landscape by registering today.
About Frost & Sullivan:
Frost & Sullivan, the growth pipeline company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO and the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth initiatives. Frost & Sullivan leverages over 60 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 40 offices on six continents.
To engage with our growth experts for more information, click here
Media Contact: María Briceñ[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/harnessing-generative-ai-in-healthcare-and-improving-cardiometabolic-health-with-precision-medicine-key-opportunities-and-insights-302283279.html

Continue Reading
Advertisement

Artificial Intelligence

Creative Innovation & Investment Shine On Day Two of Global Health Exhibition in Riyadh

Published

on

creative-innovation-&-investment-shine-on-day-two-of-global-health-exhibition-in-riyadh

World class exhibitors showcase opportunities and challenges posed by frontier-pushing digital and practical health technologies, set to revolutionize patient care for the next decade  Attendees exposed to AI-enabled diagnostic solutions, which expedite disease identification and promote fast access to treatment pathwaysStability, support and opportunity hallmarks of KSA’s high-growth investment environment to promote sustainable health ecosystemRIYADH, Saudi Arabia, Oct. 22, 2024 /PRNewswire/ — Global Health Exhibition, under the patronage of the Saudi Ministry of Health and organized by Tahaluf, continued into its second day with key sessions focussing on the breadth and depth of healthcare innovation.

Sessions included a focus on next generation pharma treatments, surgical technology, and digital health interventions. Advances in hospital technology, including emergency care, rapid stroke support and long term patient management also featured across the event’s five stages and three exhibition halls.
In addition, panel discussions addressed key topics, such as the future of oncology, early detection and advanced therapies, cardiovascular disease, cyber-security in healthcare, and the evolving investment environment. 
“Early diagnosis saves lives,”  said Dr. Danuta Jeziorska, CEO & Co-Founder, Nucleome Therapeutics at the Digital Health Forum. “We are in an era of the convergence of technologies, such as AI and genomics. The future of oncology and diagnosing patients is focused on acting early – on the Stage one of Cancer – or even to prevent it.
“For example, in the UK, the survival rate for Stage one breast cancer diagnosis is almost 100%. But by Stage four, the survival rate is 25%. I’m sitting here today, because I was diagnosed very quickly.”
The Leaders’ Summit heard from leading health sector author Mark Brignall, who discussed the global health workforce crisis, highlighted by the World Health Organization, which reveals acute staffing shortages across state owned health systems worldwide. The crisis, if unaddressed, will make most countries’ health systems unsustainable, with an estimated worldwide staff shortfall of 18 million by 2030, he explained. 
Speaking on a panel entitled “Cybersecurity in Healthcare: Safeguarding Electronic Health Records”, speakers emphasized the importance of maintaining trust when managing data at societal level, so that huge benefits can be unlocked from patient data.
“If people don’t trust us to look after their data safely, and to use it appropriately, they won’t share it with us,” said Simon Swift, CEO, Health Navigator.
“If we can’t access population-wide data, there are many things we can’t do, and we can’t keep populations, or individuals, safe. Trust is a slippery commodity – hard to gain, very easy to lose.”
Speakers also addressed the investment opportunities across the evolving medtech and pharmaceutical landscape in Saudi Arabia.
“Investors are constantly looking for growth,” said Dr Leonid Shapiro, Managing Partner, Candesic at the Investor Forum. “The Kingdom of Saudi Arabia represents somewhere where there is plenty of support, stability and opportunity.
“One of the biggest ambitions of the Ministry of Health here is to create a sustainable healthcare system. It’s not just about meeting current needs, but thinking about future needs.
“The population of the Kingdom is skyrocketing. Looking after that population can’t be a burden placed on some companies and hospitals, instead it will be necessary to attract investors, to sell services, and to invest in physical services. That’s what creates sustainability, and that’s what’s so exciting about investing here.” added Dr Shapiro.
“As the story of Global Health Exhibition 2024 continues, the event today focused not just on exciting, boundary-pushing technology, but the crunch issues that matter to health stakeholders worldwide,” said Rachel Sturgess, Group Director, Tahaluf.
“Ongoing risks around system sustainability for the long term, the continued threat of cybersecurity compromises as well as the increasing cost of care as population numbers rise are very real challenges which require creative, expert thinking to resolve. The Exhibition is acting as a vital conduit for these important discussions between Saudi Arabia and the rest of the world.”

View original content:https://www.prnewswire.co.uk/news-releases/creative-innovation–investment-shine-on-day-two-of-global-health-exhibition-in-riyadh-302283547.html

Continue Reading

Artificial Intelligence

AIMed 2024: A Pioneer in Healthcare Innovation to Join Key AI in Medicine Event

Published

on

aimed-2024:-a-pioneer-in-healthcare-innovation-to-join-key-ai-in-medicine-event

SAN ANTONIO, Oct. 22, 2024 /PRNewswire/ — Frost & Sullivan proudly announce that Reenita Das, Partner and Senior Vice President of Healthcare & Life Sciences, will attend the highly anticipated AIMed 2024 Global Summit. The event, held from November 17 – 19, 2024, 2024, will bring together healthcare leaders and AI innovators from across the globe at Caribe Royale Orlando to discuss the transformative impact of artificial intelligence in healthcare.

Reenita will serve as Co-Chair and Kickoff Speaker for the “AI and Its Impact on Women’s HealthTech” track on Monday, November 18. This track is an educational program organized by Dr. Anthony Chang, Reenita Das, and Harry P. Pappas, founder of the Women’s Health and Wellness Society, an educational and advocacy group for women. Pappas is also the founder of the Intelligent Health Association and has collaborated with Frost & Sullivan for over 15 years.
AIMed 2024 is the premier global event for artificial intelligence in healthcare, providing an ideal platform for industry experts like Reenita Das to share insights on leveraging AI to enhance healthcare systems and transform clinical workflows. Attendees will benefit from keynote speeches, hands-on workshops, and networking opportunities with top professionals worldwide.
“I’m thrilled to be part of AIMed 2024, where we will explore the critical role AI plays in addressing global healthcare challenges and improving patient outcomes,” said Reenita Das. “This summit represents an opportunity for healthcare leaders to share their vision and collaborate on advancing the future of medicine.”
Frost & Sullivan’s strategic involvement in AIMed 2024 further highlights its commitment to fostering innovation and growth in healthcare. With a unique blend of AI and healthcare technology expertise, Reenita Das will contribute to impactful discussions on applying AI-driven solutions for real-world healthcare challenges.
Why This Partnership Matters: 
AIMed24 is committed to building long-term partnerships with key organizations that share its vision of improving healthcare through AI. Frost & Sullivan’s expertise in identifying growth opportunities and their forward-looking approach to industry trends makes them an ideal partner. Together, AIMed24 and Frost & Sullivan will deliver a unique, high-value experience for attendees, ensuring they leave equipped with actionable strategies and insights to drive AI innovation in healthcare.
About Frost & Sullivan
For over six decades, Frost & Sullivan has guided the world’s top companies toward transformational growth journeys that result in a stream of innovative growth opportunities. Frost’s Growth Pipeline as a Service (GPaaS) value proposition allows customers to maximize their economic potential, navigate emerging megatrends, and shape a future based on sustainable growth. Learn more.
About AIMed24
AIMed24 is where AI and medicine’s brightest minds converge to shape the future of healthcare. Join us at the Caribe Royale Orlando from November 17-19 for groundbreaking keynotes, hands-on workshops, and exceptional networking opportunities with industry leaders. Founded by Dr. Anthony Chang, AIMed is a clinician-led community advancing AI in health. AIMed24 will showcase impactful smart healthcare solutions, facilitate connections with AI trailblazers, and engage with top institutions and innovators. Be at the forefront of healthcare innovation. Learn more.
Media Contact: María Briceñ[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/aimed-2024-a-pioneer-in-healthcare-innovation-to-join-key-ai-in-medicine-event-302283393.html

Continue Reading

Artificial Intelligence

G42 Appoints Ali Dalloul as Group Chief Strategy Officer

Published

on

g42-appoints-ali-dalloul-as-group-chief-strategy-officer

ABU DHABI, UAE, Oct. 22, 2024 /PRNewswire/ — G42, a leading AI and cloud computing company, announced today a significant addition to its leadership team with the appointment of Ali Dalloul, a seasoned American technology executive.

With three decades of leading and delivering cloud and AI programs at Microsoft, Dalloul brings an exceptional track record that aligns with G42’s strategic objectives to drive growth globally. Dalloul, who previously served as Microsoft Vice President of Azure AI Customer Experience Engineering, brings a wealth of operating experience in AI commercialization, enterprise adoption, and product strategy.
Peng Xiao, Group CEO of G42, expressed his enthusiasm about Dalloul’s appointment, stating, “Ali’s arrival as our Group Chief Strategy Officer is a milestone for G42. His proven expertise and deep insight into large-scale AI programs are precisely what G42 needs for our global expansion. Ali’s leadership will be instrumental in driving our strategic initiatives and further establishing G42 as a responsible pioneer in the rapidly evolving AI landscape.”
Ali Dalloul added: “Joining G42 marks an exciting new chapter in my career. I am honored to be part of a team that is at the forefront of AI innovation, which I have experienced personally over the past year. G42’s commitment to leveraging AI for positive global impact aligns with my own vision of how technology can reshape industries and improve lives. I look forward to advancing this mission together and unlocking the next generation of AI capabilities.”
Based in the United States, Dalloul will also serve as Chief Executive Officer of the G42 US business. In this capacity, he will spearhead the company’s US operations, driving key projects across G42’s multiple product lines and extensive partnership ecosystem.
This news follows the recent visit by the UAE’s national leadership to the US, which solidified the UAE’s role as a key international partner in the US technology agenda.
About G42
G42 is a global leader in AI and cloud computing, committed to delivering cutting-edge solutions that enable government and enterprise organizations to unlock the potential of technology at scale. Headquartered in Abu Dhabi, G42 operates at the intersection of AI, data, and digital transformation, fostering innovation across industries such as healthcare, energy, space, and finance.
To know more visit www.g42.ai.
Media ContactTrailRunner [email protected]
Photo – https://mma.prnewswire.com/media/2537136/Ali_Dalloul.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/g42-appoints-ali-dalloul-as-group-chief-strategy-officer-302283286.html

Continue Reading

Trending